Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45 results about "Feeding disorder" patented technology

A feeding disorder, in infancy or early childhood, is a child's refusal to eat certain food groups, textures, solids or liquids for a period of at least one month, which causes the child to not gain enough weight, grow naturally or cause any developmental delays. Feeding disorders resemble failure to thrive, except that at times in feeding disorder there is no medical or physiological condition that can explain the very small amount of food the children consume or their lack of growth. Some of the times, a previous medical condition that has been resolved is causing the issue.

External pulse generator for adjunct (add-on) treatment of obesity, eating disorders, neurological, neuropsychiatric, and urological disorders

An external pulse generator comprising a primary coil and adapted to inductively couple to an implanted receiving means, is designed to deliver neuromodulation therapy for disorders comprising obesity, eating disorders, anxiety and the like. The external pulse generator contains limited number of predetermined programs. These programs provide the patient or caretaker a means to adjust the therapy within confined limits, or turn the device off. The predetermined programs contain unique combination of pulse amplitude, pulse width, frequency of stimulation, and on-off time. In another mode of operation, the parameters can be individually adjusted and the stimulation therapy program can be “customized” for the patient, and stored in the memory. The programs are capable of being modified with a programming station connected to the pulse generator with a RS232-C serial connection. Additionally, the external pulse generator has two-way wireless capabilities, whereby enabling the physicians to remotely control the therapy programs of their patients using wireless internet. Moreover, the external pulse generator has proximity sensing and feedback regulation component to provide a constant therapy in accordance with the predetermined programs.
Owner:NEURO & CARDIAC TECH

Use of exendins for the reduction of food intake

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:ASTRAZENECA PHARMA LP

Photoreceptor system for melatonin regulation and phototherapy

The present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm; a light meter system for quantifying light which stimulates or regulates mammalian circadian, photoneural, and neuroendocrine systems. The present invention also relates to translucent and transparent materials, and lamps or other light sources with or without filters capable of stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals. Additionally, the present invention involves treatment of mammals with a wide variety of disorders or deficits, including light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficits, hormone-sensitive cancers, and cardiovascular disorders.
Owner:THOMAS JEFFERSON UNIV +2

Combination of atypical antipsychotics and 5HT-1B receptor antagonists

InactiveUS20050256112A1Reduce morbidityDifferent recognizableNervous disorderMetabolism disorderDiseaseHeadaches
The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.
Owner:PFIZER INC

Bombesin receptor antagonists

Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein j, k, l, m, n, q, r, Ar, Ar<1>, R<1>, R<2>, R<3>, R<4>, R<5>, R<6 >and X are as defined in the description. The compounds of the invention have an affinity for the BB1 receptor and some of them also have affinity for the BB2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.
Owner:WARNER-LAMBERT CO

Double-rotor scrap steel crusher and crushing method

The invention discloses a double-rotor scrap steel crusher. The double-rotor scrap steel crusher comprises a feeding groove and a crushing bin, wherein the crushing bin comprises a box body and at least two crushing shafts, the crushing shafts are rotationally arranged in the box body in a driven mode, a plurality of crushing hammers are arranged on the crushing shafts, and a feeding hole of the crushing bin is positioned above one sides of the end parts of the crushing shafts. According to the double-rotor scrap steel crusher, the feeding mode that feeding is carried out above the end sides of the crushing shafts is adopted in a breakthrough mode, so that crushed materials are crushed while axially advancing along the crushing shafts, the crushing time is long, the breaking and striking points are large, and the large pieces of materials can be effectively crushed. In addition, due to the fact that the crushing hammers cannot be arranged on the material falling point side, the influence of the falling materials on the crushing hammers is effectively reduced, and the accidents such as jamming at the material falling point are avoided. Moreover, the feeding hole is formed in one side of the end part, so that the falling materials do not interfere with the materials hit in the crushing bin, and the feeding disorder is reduced.
Owner:宋加龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products